Abstract:Introduction: Silent information regulator 1 (SIRT1) has been extensively investigated in the cardiovascular system and has been shown to play a pivotal role in mediating cell death/survival, energy production, and oxidative stress. However, the functional role of SIRT1 in pressure overload-induced cardiac hypertrophy and dysfunction remains unclear. Resveratrol (Rsv), a widely used activator of SIRT1, has been reported to protect against cardiovascular disease. We here examine whether activation of SIRT1 by Rsv attenuate pressure overload-induced cardiac hypertrophy and to identify the underlying molecular mechanisms. Methods: In vivo, rat model of pressure overload-induced myocardial hypertrophy was established by abdominal aorta constriction (AAC) procedure. In vitro, Angiotensin II (Ang II) was applied to induce hypertrophy in cultured neonatal rat cardiomyocytes (NCMs). Hemodynamics and histological analyses of the heart were evaluated. The expression of SIRT1, transforming growth factor-β1 (TGF-β1)/phosphorylated (p)-small mother against decapentaplegic (Smad)3 and hypertrophic markers were determined by immunofluorescence, real-time PCR, and Western blotting techniques. Results: In the current study, Rsv treatment improved left ventricular function and reduced left ventricular hypertrophy and cardiac fibrosis significantly in the pressure overload rats. The expression of SIRT1 was significantly reduced, while the expression of TGF-β1/p-Smad3 was significantly enhanced in AAC afflicted rat heart. Strikingly, treatment with Rsv restored the expressions of SIRT1 and TGF-β1/p-Smad3 under AAC influence. However, SIRT1 inhibitor Sirtinol (Snl) markedly prevented the effects of Rsv, which suggest that SIRT1 signaling pathway was involved in the cardiac protective effect of Rsv. In vitro studies performed in Ang II-induced hypertrophy in NCMs confirmed the cardiac protective effect of Rsv. Furthermore, the study presented that SIRT1 negatively correlated with the cardiac hypertrophy, cardiac fibrosis, and the TGF-β1/p-Smad3 expression. Conclusions: Taken together, these results indicated that activation of SIRT1 by Rsv attenuates cardiac hypertrophy, cardiac fibrosis, and improves cardiac function possibly via regulation of the TGF-β1/p-Smad3 signaling pathway. Our study may provide a potential therapeutic strategy for cardiac hypertrophy.

Expression of SIRT6 in Angiotensin II-Induced Cardiomyocyte Hypertrophy

A study on the expression of Sirt 6 in myocardial cells during hypoxia/reoxygenation

SIRT6 Suppresses Mitochondrial Defects and Cell Death Via the NF-κB Pathway in Myocardial Hypoxia/reoxygenation Induced Injury.

Sirtuin 6 Protects Cardiomyocytes from Hypertrophy in Vitro Via Inhibition of NF‐κB‐dependent Transcriptional Activity

SIRT6 suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy

SIRT6 Suppresses NFATc4 Expression and Activation in Cardiomyocyte Hypertrophy.

The Sirtuin 6 Prevents Angiotensin II-mediated Myocardial Fibrosis and Injury by Targeting AMPK-ACE2 Signaling

SIRT6 suppresses phenylephrine-induced cardiomyocyte hypertrophy though inhibiting p300.

SIRT 6 suppresses phenylephrine-induced cardiomyocyte hypertrophy though inhibiting p 300

SIRT1 Functions As an Important Regulator of Estrogen-Mediated Cardiomyocyte Protection in Angiotensin II-Induced Heart Hypertrophy

STAT3 Suppression is Involved in the Protective Effect of SIRT6 Against Cardiomyocyte Hypertrophy.

Cardioprotective Effects of SIRT6 in a Mouse Model of Transverse Aortic Constriction-Induced Heart Failure.

The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun

Ectopic Acsl6 Overexpression Partially Improves Isoproterenol-Induced Cardiac Hypertrophy In Vivo and Cardiomyocyte Hypertrophy In Vitro

Sirt1 Hyperexpression in Shr Heart Related to Left Ventricular Hypertrophy

[Comparison of Changes in Left Ventricular Gene Expression Profiles from Different Cardiac Hypertrophy Models in Rats].

Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor κB signaling.

Protective Effect of SIRT6 on Cholesterol Crystal-Induced Endothelial Dysfunction Via Regulating ACE2 Expression.

[Inhibitory Effect of Sirt3 on Proliferation of Vascular Smooth Muscle Cells Induced by Angiotensin II].

Sirtuin 6 attenuates angiotensin II-induced vascular adventitial aging in rat aortae by suppressing the NF-κB pathway

Activation of SIRT1 by Resveratrol Alleviates Pressure Overload-Induced Cardiac Hypertrophy via Suppression of TGF-β1 Signaling